Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Biosimilars: SOP for Harmonizing MCB/WCB Data with QA System – V 2.0

Posted on By


Biosimilars: SOP for Harmonizing MCB/WCB Data with QA System – V 2.0


Standard Operating Procedure for Harmonizing MCB/WCB Data with QA System in Biosimilar Development

Department Biosimilars
SOP No. SOP/BS/052/2025
Supersedes SOP/BS/052/2022
Page No. Page 1 of 10
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To define the procedure for harmonizing Master Cell Bank (MCB) and Working Cell Bank (WCB) data with Quality Assurance (QA) systems in biosimilar development, ensuring consistent documentation, traceability, and GMP compliance.

2. Scope

This SOP applies to all data related to the creation, characterization, testing, and archival of MCB and WCB records, and the processes for integration with QA-managed documentation systems.

3. Responsibilities

  • CLD Team: Generates, maintains, and updates MCB/WCB documentation in alignment with lab records.
  • QA Department: Verifies completeness and accuracy of MCB/WCB data; integrates into official QA-controlled systems.
  • Head of Biosimilars: Ensures procedural adherence and final approval of harmonized records.
See also  Biosimilars: SOP for Monitoring COâ‚‚ Levels in Incubators - V 2.0

4. Accountability

The Head of QA is accountable for ensuring that all MCB and WCB records are harmonized, traceable, and ready for internal or external audits as per regulatory standards.

5. Procedure

5.1 Creation of MCB/WCB Documentation Set

  1. Ensure the following documents are compiled post-banking:
    • Cell Bank Production Report
    • Analytical Test Results (e.g., sterility, mycoplasma, identity)
    • Cryopreservation Protocol
    • Storage Location Map

5.2 Internal Record Verification

  1. Cross-verify:
    • Banking date and passage number
    • Freezer ID and vial labeling
    • Test results and equipment calibration logs
  2. Document verification outcomes in the Record Reconciliation Sheet (Annexure-1).

5.3 QA Review and Integration

  1. Submit verified records to QA for master file integration.
  2. QA to assign QA Document ID and enter into QA Register (Annexure-2).
  3. Files to be indexed with electronic and physical folder names clearly labeled.
See also  Biosimilars: SOP for Preparation of Competent Cells - V 2.0

5.4 Discrepancy Resolution

  1. Any mismatch between lab data and QA entries must trigger a controlled deviation.
  2. Deviation must be closed prior to final approval by QA.

5.5 Archival and Audit Readiness

  1. Store harmonized documentation in QA-controlled archives.
  2. Backup electronic files on secure QA server with restricted access.
  3. Review completeness during annual GMP internal audit.

6. Abbreviations

  • MCB: Master Cell Bank
  • WCB: Working Cell Bank
  • CLD: Cell Line Development
  • QA: Quality Assurance
  • GMP: Good Manufacturing Practice

7. Documents

  1. Record Reconciliation Sheet (Annexure-1)
  2. QA Cell Bank Integration Register (Annexure-2)

8. References

  • ICH Q5D – Derivation and Characterization of Cell Substrates
  • WHO Technical Report Series 978 – Annex 3
  • 21 CFR Part 211 – Subpart J: Records and Reports
See also  Biosimilars: SOP for Cryopreservation of Cell Banks - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Record Reconciliation Sheet

Record Type CLD Entry QA Entry Verified By Date
Banking Date 28/04/2025 28/04/2025 Ajay Verma 01/05/2025

Annexure-2: QA Cell Bank Integration Register

QA Doc ID Cell Bank ID CLD File Ref Entry Date Integrated By
QA-MCB-042 MCB-CHO-017 CLD-MCB-017 01/05/2025 Sunita Reddy

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Integrated QA documentation workflow and reconciliation protocol Process Standardization
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: Analytical Method Development: Loss on Drying (LOD) Method Development – V 2.0
Next Post: Creams: SOP for Particle Size Analysis in Cream Emulsions – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version